GlycoPEGylated recombinant factor IX for hemophilia B in context

Decisions over hemophilia treatment selection and switching involve balancing many clinical and patient-related factors. The current standard of care for patients with hemophilia B is prophylaxis with plasma-derived or recombinant factor IX (rFIX) concentrates. However, several extended half-life (E...

Descripción completa

Detalles Bibliográficos
Autores principales: Santagostino, Elena, Mancuso, Maria Elisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141116/
https://www.ncbi.nlm.nih.gov/pubmed/30254423
http://dx.doi.org/10.2147/DDDT.S121743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141116/
https://www.ncbi.nlm.nih.gov/pubmed/30254423
http://dx.doi.org/10.2147/DDDT.S121743

Ejemplares similares